MedPath

Maintaining Nonsmoking: Older Smokers - 1

Phase 3
Completed
Conditions
Tobacco Use Disorder
Interventions
Registration Number
NCT00086385
Lead Sponsor
University of California, San Francisco
Brief Summary

The purpose of this study was to examine pharmacological and psychological interventions for smokers over 50.

Detailed Description

The overall goals of this line of research were to prevent relapse to cigarette smoking, and to understand the processes related to smoking and relapse. The specific aims of the current study were to test a series of hypotheses about the efficacy and cost-effectiveness of long-term, tailored interventions in chronic, older smokers and the interaction of these interventions with gender and depression. Participants were 50 years or older and smoker 10 or more cigarettes per day. Baseline assessments includes measures of smoking behavior, nicotine dependence, depression diagnosis, demographics and life circumstances and measures of anger, depression and mood disturbance, stress, social support, health status, motivation for changed and drug and alcohol use.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
403
Inclusion Criteria

MULTIPLE

Exclusion Criteria

MULTIPLE

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Extended NRTNicotine polacrilex, BupropionPharmacological Treatment - Following completion of the Brief Treatment, subjects assigned to this condition would continue receiving NRT for up to 52 weeks. Subjects in this condition would be encouraged to continue NRT through Week 24. If a subject terminated NRT and resumed smoking, before Week 50, would be instructed to set a quit date and resume NRT. Counseling Treatment - This is identical to the Brief Counseling described above.
Extended Tailored Counseling + NRTNicotine polacrilex, BupropionTailored Counseling Treatment- The primary goal of the extended treatment was to prevent relapse. Secondary goal was to encourage initiation of abstinence for those who have not attained it by Week 12, and re-initiation of abstinence after slips. Subjects would participate in the Brief Treatment followed by individual sessions. The first extended treatment counseling session would occur at Week 10. Additional sessions would be held every two weeks then every four weeks, and finally at Weeks 44 and 52. Each session would be 20-30 minutes long. Between sessions subjects would be contacted by phone for brief check-ins (5-10 minutes).
Brief TreatmentNicotine polacrilex, BupropionPharmacological Treatment - Subjects received 12 weeks of bupropion treatment and 10 weeks of nicotine replacement treatment (NRT) Brief Counseling - The counseling intervention consisted of five 90-minute group meetings. There was no further treatment during Weeks 12-52.
Tailored/No Extended NRTNicotine polacrilex, BupropionThis condition was identical to the Tailored/NRT condition except that no NRT was available after completion of the Brief Treatment.
Primary Outcome Measures
NameTimeMethod
Participants Abstinent From CigarettesTwo years

Primary outcome variable was 7-day point prevalence cigarette abstinence verified biochemically at week 104

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

San Francisco

🇺🇸

San Francisco, California, United States

© Copyright 2025. All Rights Reserved by MedPath